Cut to the Bone: Amgen Faces Further Aranesp Decline Ahead of Denosumab
This article was originally published in RPM Report
Executive Summary
When it comes to Amgen, all eyes are on denosumab. That's as it should be: Amgen's future rides on the potential blockbuster. But investors shouldn't lose sight of Amgen's past and present: how the company manages the continued threats to Aranesp have important lessons for the biopharma sector as a whole-and for denosumab too.